Tae-yong Y. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 171 publications

Addressing Existential Distress Through Compassion: Feasibility and Preliminary Effects of Compassion With You (COMwithU), a Compassion-Based Intervention for Patients With Cancer.

Addressing Existential Distress Through Compassion: Feasibility and Preliminary Effects of Compassion With You (COMwithU), a Compassion-Based Intervention for Patients With Cancer.

Journal: Psycho-oncology

Published: May 03, 2026

An Improved YOLOv9 Based Object Detection with Attention Mechanism for Personal Protective Equipment.

An Improved YOLOv9 Based Object Detection with Attention Mechanism for Personal Protective Equipment.

Journal: Sensors (Basel, Switzerland)

Published: March 17, 2026

Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.

Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.

Journal: The oncologist

Published: March 03, 2026

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

Journal: International journal of clinical oncology

Published: December 04, 2025

Unexpected Cancellation of Radioactive Iodine Treatment after Thyroid Hormone Withdrawal: Lessons from a Case Series.

Unexpected Cancellation of Radioactive Iodine Treatment after Thyroid Hormone Withdrawal: Lessons from a Case Series.

Journal: Endocrinology and metabolism (Seoul, Korea)

Published: November 18, 2025

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Journal: Nature medicine

Published: November 07, 2025

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.

Journal: British journal of cancer

Published: November 03, 2025

Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression.

Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression.

Journal: Cell communication and signaling : CCS

Published: June 13, 2025

Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Journal: Journal of hepatology

Published: May 10, 2025

Analysis of T Cell Subsets Using Multiplex Immunohistochemistry and Clinical Outcomes of Immune Checkpoint Inhibitors in Advanced Gastric Cancer Patients.

Analysis of T Cell Subsets Using Multiplex Immunohistochemistry and Clinical Outcomes of Immune Checkpoint Inhibitors in Advanced Gastric Cancer Patients.

Journal: Cancer research and treatment

Published: April 28, 2025

Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.

Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.

Journal: Journal of hepatology

Published: March 17, 2025

JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction.

JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction.

Journal: International journal of biological sciences

Published: March 13, 2025

Showing 1-12 of 171

Last Updated: 09/26/2026